Letter to the Editors: Concerning BLong-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia" by Lee et al Response

被引：1
|
作者：
Lee, Youngmok [1 ]
Chou, Janice Y. [2 ]
Weinstein, David A. [1 ]
机构：
[1] Univ Connecticut, Hlth Ctr, Farmington, CT 06030 USA
[2] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Cellular Differentiat, Bethesda, MD USA
来源：
JOURNAL OF INHERITED METABOLIC DISEASE | 2018年 / 41卷 / 06期
关键词：
PREVENTION; LIVER;
D O I：
10.1007/s10545-018-0249-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：915 / 915
页数：1
相关论文
共 46 条
  • [41] Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia (vol 13, pg 1281, 2006)
    Koeberl, D. D.
    Sun, B. D.
    Damodaran, T. V.
    Brown, T.
    Millington, D. S.
    Benjamin, D. K., Jr.
    Bird, A.
    Schneider, A.
    Hillman, S.
    Jackson, M.
    Beaty, R. M.
    Chen, Y. T.
    GENE THERAPY, 2007, 14 (03) : 281 - 281
  • [42] Sustained Efficacy and Safety at Week 52 and Up to Three Years in Adults with Glycogen Storage Disease Type iA (GSDIa): Results from a Phase 1/2 Clinical Trial of DTX401, an AAV8-mediated, Liver-Directed Gene Therapy
    Riba-Wolman, Rebecca
    Rodriguez-Buritica, David F.
    Ahmad, Ayesha
    Pico, Maria-Luz Couce
    Derks, Terry G.
    Mitchell, John
    Weinstein, David A.
    Mitragotri, Deepali
    Valayannopoulos, Vassili
    Crombez, Eric
    MOLECULAR THERAPY, 2022, 30 (04) : 564 - 564
  • [43] AAV8-Mediated Liver-Directed Gene Therapy as a Potential Therapeutic Option in Adults with Glycogen Storage Disease Type Ia (GSDIa): Updated Phase 1/2 Clinical Trial Results
    Rodriguez-Buritica, David F.
    Ahmad, Ayesha
    Pico, Mari Luz Couce
    Derks, Terry G.
    Mitchell, John
    Riba-Wolman, Rebecca
    Mou, Jiani
    Poma, Allen
    Valayannopoulos, Vassili
    Crombez, Eric
    MOLECULAR THERAPY, 2021, 29 (04) : 134 - 135
  • [44] AAV8-Mediated Liver-Directed Gene Therapy as a Potential Therapeutic Option in Adults with Glycogen Storage Disease Type Ia (GSDIa): Results from a Phase 1/2 Clinical Trial
    Weinstein, David A.
    Ahmad, Ayesha
    Rodriguez-Buritica, David F.
    Mitchell, John
    Derks, Terry G.
    Mou, Jiani
    Poma, Allen
    Crombez, Eric
    MOLECULAR THERAPY, 2020, 28 (04) : 558 - 558
  • [45] Efficacy and Safety at Week 52 and up to Four Years in Adults with Glycogen Storage Disease Type IA (GSDIa): Results from a Phase 1/2 Clinical Trial and Long-Term Follow-Up Study of DTX401, an AAV8-Mediated, Liver-Directed Gene Therapy
    Riba-Wolman, Rebecca
    Rodriguez-Buritica, David F.
    Ahmad, Ayesha
    Couce Pico, Maria-Luz
    Derks, Terry G.
    Mitchell, John
    Weinstein, David A.
    Mitragotri, Deepali
    Grimm, Andrew Alexander
    Crombez, Eric
    MOLECULAR THERAPY, 2023, 31 (04) : 2 - 3
  • [46] COHORT 1-4 RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF AN AAV8-MEDIATED LIVER-DIRECTED GENE THERAPY IN ADULTS WITH GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA)
    Rodriguez-Buritica, David F.
    Ahmad, Ayesha
    Pico, Maria-Luz Couce
    Derks, Terry G.
    Mitchell, John
    Riba-Wolman, Rebecca
    Weinstein, David A.
    Lee, Connie
    Valayannopoulos, Vassili
    Crombez, Eric
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (04) : 296 - 296
12345